Bruker
BRKR
$54.39
+11.87%
Bruker Corporation is a leading manufacturer of high-performance scientific instruments and diagnostic tests, serving customers in the life sciences, pharmaceutical, biotechnology, and applied materials industries. The company operates as a specialized technology leader, with its Bruker Scientific Instruments (BSI) segment, particularly the BSI CALID division, being its primary revenue driver, focusing on mass spectrometry and molecular spectroscopy. The current investor narrative centers on navigating a period of volatile financial performance, as evidenced by recent quarterly results swinging from profitability to significant losses, raising questions about the sustainability of its growth trajectory and operational execution in a competitive capital equipment market.…
BRKR
Bruker
$54.39
BRKR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker's 12-month outlook, with a consensus price target around $70.71 and implied upside of +30.0% versus the current price.
Average Target
$70.71
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$44 - $71
Analyst target range
Analyst coverage is limited, with only 6 analysts providing estimates, indicating this is a mid-cap stock with less institutional scrutiny, which can lead to higher volatility and less efficient price discovery. The available data shows consensus estimates for EPS and revenue but does not provide a consensus price target or Buy/Hold/Sell distribution; therefore, insufficient analyst coverage is available to determine a clear sentiment or implied upside/downside. The lack of a defined target range from the provided data means uncertainty is high, and investors must rely more heavily on independent fundamental and technical analysis rather than analyst consensus for investment decisions.
Bulls vs Bears: BRKR Investment Factors
The evidence is finely balanced but leans bearish due to the company's fundamental instability. The bull case rests on deep valuation and a strong technical rebound from oversold levels, suggesting the market has over-penalized the stock. The bear case is grounded in severe quarterly earnings volatility, stalled revenue growth, and questionable profitability that challenge the sustainability of any rally. The single most important tension in the investment debate is whether the recent quarterly profit of $26 million and 47.8% gross margin signal a sustainable operational turnaround, or if the preceding quarter's $59.6 million loss is indicative of an inherently volatile, lumpy business model that cannot support a stable valuation multiple.
Bullish
- Deeply Undervalued on Sales: The stock trades at a trailing Price-to-Sales ratio of 2.08, near the bottom of its historical range, which has been as high as 20.14. This suggests significant multiple compression has occurred, potentially pricing in excessive pessimism. A forward PS of ~1.67, based on analyst revenue estimates, indicates the market expects minimal growth, setting a low bar for positive surprises.
- Strong Recent Technical Rebound: The stock has surged 15.18% over the past month and 19.36% over the past three months, significantly outperforming the S&P 500's 4.84% and 8.15% gains, respectively. This indicates a powerful relief rally from oversold conditions, with the current price of $45.69 representing a recovery from a 52-week low of $28.53, suggesting potential momentum shift.
- Solid Balance Sheet and Liquidity: The company maintains a manageable debt-to-equity ratio of 0.83 and a healthy current ratio of 1.73, indicating sufficient liquidity to meet short-term obligations. Positive free cash flow of $207.2 million in the latest quarter provides operational flexibility and reduces near-term financial risk.
- Analyst Revenue Growth Expectations: Analysts project forward revenue of approximately $4.28 billion, which implies a significant sequential increase from the latest quarterly revenue of $977.2 million if annualized. This expectation, embedded in the forward PS ratio of ~1.67, provides a fundamental growth anchor that, if met, could support a higher valuation.
Bearish
- Severe Earnings and Revenue Volatility: The company's financial performance is highly inconsistent, swinging from a net income of $26 million in Q4 2025 to a loss of -$59.6 million in Q3 2025. Revenue growth has stalled, with the latest quarter showing a -0.24% YoY decline, indicating a lack of consistent top-line momentum in a competitive capital equipment market.
- Negative Profitability and High Valuation Multiples: Trailing EPS is negative at -$0.0012, rendering the trailing P/E meaningless and the forward P/E of 18.9 potentially misleading if earnings fail to materialize. The Price-to-Cash Flow ratio is extremely high at 53.33, and the PEG ratio of 6.94 suggests growth is expensive relative to earnings expectations, raising valuation risk.
- Technical Downtrend and High Volatility: Despite the recent rebound, the stock remains in a clear downtrend from its 52-week high of $56.22, trading near the lower 31% of its annual range. Its beta of 1.122 indicates it is 12% more volatile than the market, which, combined with a -3.34% return over the past six months, signals higher risk and potential for further downside.
- Weak Free Cash Flow Generation: While the latest quarter showed positive FCF, the trailing twelve-month free cash flow is only $43.3 million on a market cap of $7.15 billion, representing a meager 0.6% yield. This weak cash generation limits the company's ability to fund growth, pay down debt, or return capital to shareholders without external financing.
BRKR Technical Analysis
The stock is in a pronounced downtrend from its 52-week highs, with a 1-year price change of +25.73% that masks a severe recent correction; the current price of $45.69 sits at approximately 31% of its 52-week range ($28.53 to $56.22), indicating it is trading much closer to its annual lows than its highs, which suggests deep value territory but also significant bearish momentum. Recent momentum shows a sharp divergence, with a strong 1-month gain of +15.18% and a 3-month gain of +19.36%, signaling a potential short-term rebound or relief rally from deeply oversold conditions, though this is against a backdrop of a -3.34% loss over the past six months. Key technical support is clearly defined at the 52-week low of $28.53, while resistance looms at the 52-week high of $56.22; a sustained breakout above the recent recovery highs near $54 would be needed to signal a trend reversal, while the stock's beta of 1.122 indicates it is approximately 12% more volatile than the broader market, which is a consideration for risk-adjusted positioning.
Beta
1.12
1.12x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$29-$56
Price range past year
Annual Return
+47.1%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | +50.0% | +6.0% |
| 3m | +35.6% | +10.0% |
| 6m | +11.4% | +10.4% |
| 1y | +47.1% | +28.4% |
| ytd | +13.1% | +10.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Revenue growth has stalled, with the most recent quarterly revenue of $977.2 million showing a slight year-over-year decline of -0.24%, and the multi-quarter trend reveals high volatility, from $721.7M in Q1 2024 to $977.2M in Q4 2025, indicating lumpy order patterns rather than consistent expansion. Profitability is highly inconsistent, with the latest quarter showing net income of $26 million and a gross margin of 47.77%, but the preceding Q3 2025 posted a net loss of -$59.6 million with a gross margin of 44.88%, highlighting severe margin compression and earnings volatility that complicates the investment thesis. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.83, and while the company generated positive free cash flow of $207.2 million in the latest quarter, the trailing twelve-month FCF is $43.3 million, suggesting internal funding for growth is possible but not robust, and the current ratio of 1.73 indicates adequate short-term liquidity.
Quarterly Revenue
$977200000.0B
2025-12
Revenue YoY Growth
+0.00%
YoY Comparison
Gross Margin
+0.47%
Latest Quarter
Free Cash Flow
$43300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Given the trailing net income is marginally negative at -$0.0012 per share, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 2.08, and while a forward PS is not explicitly provided, the market cap of $7.15 billion against analyst revenue estimates of ~$4.28 billion implies a forward PS of approximately 1.67, suggesting the market expects some revenue growth and potential margin improvement. Compared to sector averages, data is not available for a direct Medical Devices industry PS comparison, but a trailing PS of 2.08 appears reasonable for a cyclical instrumentation company, though the discount implied by the forward multiple suggests cautious expectations. Historically, the stock's own PS ratio has fluctuated wildly, from a high of 20.14 in mid-2021 down to the current 2.08, indicating the stock is trading near the very bottom of its historical valuation band, which could signal a deep value opportunity if fundamentals stabilize, or a justified discount due to deteriorating business prospects.
PE
-831.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -21x~302x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: BRKR faces significant financial risk from its highly volatile earnings, as demonstrated by the swing from a $59.6M loss in Q3 2025 to a $26M profit in Q4 2025. This earnings instability, coupled with a stagnant revenue trend (latest quarter YoY growth of -0.24%), makes forecasting difficult and increases investment uncertainty. The company's modest free cash flow generation—TTM FCF of $43.3M against a $7.15B market cap—limits its financial flexibility for strategic investments or shareholder returns without taking on additional debt, which currently stands at a D/E of 0.83.
Market & Competitive Risks: The primary market risk is valuation compression. The stock's trailing PS of 2.08 is near its historical lows, but its forward P/E of 18.9 and extremely high P/CF of 53.3 suggest the market is pricing in a significant earnings recovery. If this recovery fails to materialize, multiples could contract further. As a cyclical capital equipment provider in the healthcare sector, BRKR is sensitive to reductions in R&D and capital expenditure budgets from its pharmaceutical and biotech customers. Its beta of 1.122 indicates it is more volatile than the market, amplifying downside during broader sell-offs.
Worst-Case Scenario: The worst-case scenario involves a continuation of operational missteps, leading to another significant quarterly loss, a breakdown in gross margins below 44%, and a subsequent guidance withdrawal. This could trigger a loss of investor confidence, analyst downgrades, and a re-rating to distressed valuation levels. A realistic downside could see the stock retesting its 52-week low of $28.53, representing a potential loss of approximately -38% from the current price of $45.69. The historical max drawdown of -39.85% provides a precedent for such a decline.